Kravitz AV, Freeze BS, Parker PR, Kay K, Thwin MT, Deisseroth K, et al
The consistent finding across this body of work: no evidence of carcinogenic potential
The proposed mechanism involves selective stimulation of fat breakdown (lipolysis) and suppression of fat formation (lipogenesis) via direct effects on adipose tissue, without the growth hormone-like systemic effects
Administration less frequent than twice weekly likely allows complete dissipation of synaptic changes between doses, preventing the cumulative structural modifications that constitute Dihexas therapeutic mechanism
Side Effects & Safety No lethal dose found -- toxicology studies couldn't establish an LD50 (Sikiric et al., 2006) No organ toxicity in chronic dosing No hormonal effects -- doesn't affect testosterone, estrogen, cortisol, or GH Mild nausea -- mostly with oral dosing Brief lightheadedness -- occasionally after injection Injection site redness -- standard for SC peptides Angiogenesis concern -- promotes new blood vessel growth, which raises a theoretical question about existing tumors
